Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arun A Azad

Showing results (21-30 of 140) with videos related to

Pageof 14
Sort By:
European Urology|January 9, 2019
Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and TheranosticsDeclan G Murphy, Arun A Azad, Shahneen Sandhu, et al.
European Urology Focus|December 24, 2025
Reply to Tonghu Liu, Congcong Zhu, and Zechen Yan's Letter to the Editor re: Heidi Fettke, Louise Kostos, Maria Docanto, et al. Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [<sup>177</sup>Lu]Lu-PSMA-617. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.08.015Louise Kostos, Heidi Fettke, Tu Nguyen-Dumont, et al.
Urologic Oncology|April 13, 2024
Precision medicine for prostate cancer: An international perspectiveAnis A Hamid, Christopher J Sweeney, Christopher Hovens, et al.
European Urology|July 15, 2014
Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patientsArun A Azad, Bernhard J Eigl, R Nevin Murray, et al.
Current Opinion in Supportive and Palliative Care|October 14, 2022
Systemic therapy in metastatic hormone-sensitive prostate cancerJodie McDonald, Jonathan O'Brien, Louise Kostos, et al.
Future Oncology (London, England)|October 15, 2024
Enzalutamide in metastatic hormone-sensitive prostate cancer: A plain language summary of the ARCHES and ENZAMET follow-up studiesAndrew J Armstrong, Arun A Azad, Ciara Conduit, et al.
Clinical Genitourinary Cancer|June 22, 2016
Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell CarcinomaMatti Annala, Lucia Nappi, Arun A Azad, et al.
The Medical Journal of Australia|October 13, 2020
Understanding the diagnosis of prostate cancerXuan Rui S Ong, Dominic Bagguley, John W Yaxley, et al.
Melanoma Research|January 28, 2014
A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programmeDavid K Lau, Miles C Andrews, Natalie Turner, et al.
Oncotarget|November 28, 2014
PD-L1 is highly expressed in Enzalutamide resistant prostate cancerJennifer L Bishop, Alexander Sio, Arkhjamil Angeles, et al.
Pageof 14

Showing results (21-30 of 140) with videos related to

Sort By:
Pageof 14
European Urology|January 9, 2019
Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and TheranosticsDeclan G Murphy, Arun A Azad, Shahneen Sandhu, et al.
European Urology Focus|December 24, 2025
Reply to Tonghu Liu, Congcong Zhu, and Zechen Yan's Letter to the Editor re: Heidi Fettke, Louise Kostos, Maria Docanto, et al. Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [<sup>177</sup>Lu]Lu-PSMA-617. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.08.015Louise Kostos, Heidi Fettke, Tu Nguyen-Dumont, et al.
Urologic Oncology|April 13, 2024
Precision medicine for prostate cancer: An international perspectiveAnis A Hamid, Christopher J Sweeney, Christopher Hovens, et al.
European Urology|July 15, 2014
Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patientsArun A Azad, Bernhard J Eigl, R Nevin Murray, et al.
Current Opinion in Supportive and Palliative Care|October 14, 2022
Systemic therapy in metastatic hormone-sensitive prostate cancerJodie McDonald, Jonathan O'Brien, Louise Kostos, et al.
Future Oncology (London, England)|October 15, 2024
Enzalutamide in metastatic hormone-sensitive prostate cancer: A plain language summary of the ARCHES and ENZAMET follow-up studiesAndrew J Armstrong, Arun A Azad, Ciara Conduit, et al.
Clinical Genitourinary Cancer|June 22, 2016
Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell CarcinomaMatti Annala, Lucia Nappi, Arun A Azad, et al.
The Medical Journal of Australia|October 13, 2020
Understanding the diagnosis of prostate cancerXuan Rui S Ong, Dominic Bagguley, John W Yaxley, et al.
Melanoma Research|January 28, 2014
A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programmeDavid K Lau, Miles C Andrews, Natalie Turner, et al.
Oncotarget|November 28, 2014
PD-L1 is highly expressed in Enzalutamide resistant prostate cancerJennifer L Bishop, Alexander Sio, Arkhjamil Angeles, et al.
Pageof 14